CONTACTS:
Michael Blash Zeneca Pharmaceuticals
302-886-5465
[email protected]
FOR IMMEDIATE RELEASE
PROSTATE CANCER WEB SITE LAUNCHED BY ZENECA PHARMACEUTICALS
Web Site Emphasizes Understanding the Disease Before or After a Diagnosis of Prostate Cancer
Wilmington, Del. - June 11, 1998 - Zeneca Pharmaceuticals has launched a new prostate cancer educational web site for individuals and medical professionals who are affected by prostate cancer. The new web site, http://www.prostateinfo.com, is a vehicle to support the ongoing commitment of Zeneca to education by providing information to health care professionals and the public to better prepare for a possible diagnosis of cancer and ensuing treatment options.
The www.prostateinfo.com links take a viewer through an educational course to understand prostate cancer, its diagnosis, and available treatment options. Illustrations help viewers better understand the disease, and there is a section on coping with prostate cancer which includes a list of cancer support services. In addition, printed educational material is offered, free of charge, on the web site.
"Zeneca has a long history of providing quality, objective information about prostate cancer to men and their families through their physicians," said Mark Rickards, Zeneca Senior Product Manager of Oncology Products. "Making the same information available directly to the public through this web site is a logical extension of our commitment to service."
According to the American Cancer Society, it is estimated 184,500 new cases of prostate cancer will be diagnosed, and an estimated 39,200 men will die from the disease in the United States during 1998. Early diagnosis and medical information may help save lives. Through education, it is hoped that men across the world will discuss the disease with their health care professionals and take advantage of the services available that encourage early detection.
Zeneca is a leading pharmaceutical company in oncology care, with two major hormonal therapies for the treatment of prostate cancer. CASODEX(R) (bicalutamide) Tablets is an orally administered antiandrogen used in combination with a lutenizing hormone-releasing hormone analogue (LHRH-A) for the treatment of metatstatic D2 prostate cancer and ZOLADEX(R) (goserelin acetate implant) is an LHRH-A for the treatment of advanced prostate cancer. Other web sites from Zeneca provide information on migraine (www.zomig.com), asthma (www.accolateinfo.com), anesthetics (www.diprivan.com), and National Breast Cancer Awareness Month (www.nbcam.com).
Zeneca Pharmaceuticals is a business unit of Zeneca Inc. In the United States, Zeneca Inc. is a $3.4 billion bioscience business with approximately 7,500 employees. Zeneca Inc. is a wholly-owned subsidiary of the UK-based Zeneca Group PLC (NYSE:ZEN), a major $8.6 billion international bioscience business engaged in the research, development, manufacture, and marketing of ethical (prescription) pharmaceuticals, agricultural and specialty chemical products, and the supply of health care services.
For full prescribing information, please call 1-800-456-3669, extension 2231.
# # #
RSS